Organizations Filed Purposes:
A NONPROFIT SCIENTIFIC RESEARCH ORGANIZATION DEDICATED TO ADDRESSING URGENT, UNMET GLOBAL HEALTH CHALLENGES INCLUDING HIV AND TUBERCULOSIS. THE ORGANIZATION'S MISSION IS TO TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS.
TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS
RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS. THIS INCLUDES THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE THE HIV BURDEN IS GREATEST. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 837,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS AND LASSA FEVER, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST.
CONTRACT MANUFACTURING-RELATED ACTIVITIES: IAVI SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS.
VACCINE ADVOCACY, PUBLIC AFFAIRS, AND POLICY: IAVI WORKS WITH POLICY MAKERS, ADVOCATES, AND REPRESENTATIVES OF THE COMMUNITIES WHERE DISEASE BURDEN IS GREATEST TO SUPPORT SCIENTIFIC RESEARCH AND DEVELOPMENT FOR ACCESSIBLE BIOMEDICAL PREVENTIVES AND TREATMENTS.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
Name | Title | Hours Per Week | Total Salary |
Mark Feinberg | PRESIDENT/CEO | 35 | $555,341 |
Ana Cespedes Montoya | CHIEF OPERATING OFFICER | 35 | $424,619 |
Labeeb Abboud | SECRETARY, SR VP, GENERAL COUNSEL | 35 | $375,304 |
Thomas Hassell | VP VACCINE DEVELOPMENT R&D | 35 | $333,344 |
Ann Ginsberg | SENIOR TECHNICAL ADVISOR | 35 | $324,265 |
Christopher Parks | EXECUTIVE DIR., VIRAL VACCINES | 35 | $314,499 |
Louis Schwartz | ASST. SEC. & CHIEF FINANCIAL OFFICER | 35 | $309,837 |
Swati Gupta | VP RESEARCH INTEGRATION & INNOVATION | 35 | $302,410 |
Margaret Keane | VP GLOBAL ALL. & PROD. OPTIMIZATION | 35 | $290,912 |
Frances Sinha | CHIEF PEOPLE OFFICER (BEG. 04/19) | 35 | $150,884 |
John Nkengasong | BOARD MEMBER | 1 | $0 |
Anne Martin Simonds | BOARD MEMBER | 1 | $0 |
John W Shiver | BOARD MEMBER | 1 | $0 |
David Blumberg | BOARD MEMBER | 1 | $0 |
Hon Mark Dybul | BOARD MEMBER | 1 | $0 |
Linda-Gail Becker | BOARD MEMBER | 1 | $0 |
Jim Connolly | BOARD MEMBER | 1 | $0 |
Purnima Mane | BOARD MEMBER | 1 | $0 |
Rajeev Venkayya | BOARD MEMBER | 1 | $0 |
Marijke Wijnroks | BOARD MEMBER | 1 | $0 |
Francine Ntoumi | BOARD MEMBER | 1 | $0 |
Robert Goldberg | BOARD TREASURER | 2 | $0 |
Anne M Vanlent | BOARD VICE CHAIR | 2 | $0 |
Eric Paul Goosby | BOARD CHAIR | 2 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202031849349301818_public.xml